(Hedgeweek) The incoming US administration led by Joe Biden will be a “crucial” factor looming large over the healthcare industry this year, with planned reforms heralding potentially far-reaching implications for healthcare stocks and drug prices, Rhenman & Partners Asset Management said this week.
Healthcare hedge fund Rhenman gauges “crucial” impact of Biden administration’s planned reforms
This entry was posted in Syndicated. Bookmark the permalink.
